Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07224841 · ClinicalTrials.gov registry record
Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC
A clinical trial of CRC, Colorectal Cancer, sponsored by City of Hope Medical Center.
- Recruiting
- Registry status
- 500
- Enrollment target
- 1
- Study location
NCT07224841: Recruiting study of CRC, Colorectal Cancer, sponsored by City of Hope Medical Center.
NCT07224841 is a study of CRC, Colorectal Cancer that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 500 participants, above the 271-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (85% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07224841, a study of CRC, Colorectal Cancer, is actively recruiting participants, sponsored by City of Hope Medical Center.
- RECRUITING
- Registry status
- 500 participants
- Enrollment target
- 1
- Study location
Study Summary
The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predictive biomarker panel capable of differentiating responders from non-responders to targeted therapy.
Primary Outcome
Progression-free survival (PFS) among patients with metastatic colorectal cancer (mCRC) receiving EGFR- or VEGF-targeted therapy, stratified by cfDNA 5mC/5hmC-based biomarker status.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase)
- DIAGNOSTIC_TEST EpiDRIVE Assay (Targeted Sequencing / qPCR Validation)
Study Locations (1)
California
- City of Hope Medical Center - Duarte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2024-06-21 |
| Est. Completion | 2026-06-18 |
What NCT07224841 shows while recruiting
NCT07224841 is an observational study that tracks outcomes without assigning an intervention. The registered 500 participants enrollment target is mid-sized for trials with a published cap, above the 271-participant average among 10 other CRC, Colorectal Cancer trials with a reported enrollment target (85% higher).
The record links to 1 condition, with CRC, Colorectal Cancer appearing as the primary indexed condition, and to 2 interventions - of which cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase) is the first listed.
NCT07224841 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT07224841 about?
NCT07224841 is a clinical study titled "Development of a cfDNA 5mC/5hmC-based Biomarker Panel to Predict Targeted Therapy Efficacy in mCRC". The EpiDRIVE study aims to identify cfDNA-based epigenetic determinants of response in metastatic colorectal cancer (mCRC) patients treated with EGFR- or VEGF-targeted therapy. By integrating 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC) profiling, this study seeks to develop a predicti...
What is the current status of trial NCT07224841?
This trial is currently recruiting. The enrollment target is 500 participants. The study started on 2024-06-21. Estimated completion is 2026-06-18.
What conditions does trial NCT07224841 study?
This clinical trial studies the following conditions: CRC, Colorectal Cancer.
What interventions are being tested in trial NCT07224841?
The interventions under investigation include: cfDNA 5mC/5hmC Sequencing (EpiDRIVE Discovery Phase) (DIAGNOSTIC_TEST), EpiDRIVE Assay (Targeted Sequencing / qPCR Validation) (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT07224841?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07224841 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for CRC, Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07224841's enrollment target sits among peer trials
500 3rd of 10 higher than 8 of 10 other CRC, Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other CRC, Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Study Evaluating the Safety and PK of ADU-1805 in Advanced Solid Tumors
RECRUITING · Phase 1
-
Feasibility of a Multi-Channel Intervention to Promote Colorectal Cancer Screening Among American Indians in Oklahoma
RECRUITING · NA
-
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
RECRUITING · Phase 1
-
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer
RECRUITING · Phase 3
-
BBO-11818 in Adult Subjects With KRAS Mutant Cancer
RECRUITING · Phase 1
-
cfDNA 5mC/5hmC Biomarkers to Predict Chemotherapy Response in Metastatic Colorectal Cancer
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001230 · 500 participants
Host Response to Infection and Treatment in Filarial Diseases
- NCT00001529 · 500 participants
Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- NCT00697411 · 500 participants
Study of Selected X-Linked Disorders: Aicardi Syndrome
- NCT00903110 · 500 participants
Global Patient Registry to Monitor Long-term Safety and Effectiveness of Increlex® in Children and Adolescents With Severe Primary Insulin-like Growth Factor-1 Deficiency (SPIGFD).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI